"Pfizer's Irresistible Value: A Compelling Investment Opportunity"

Pfizer's stock has dropped to a ten-year low despite reporting record revenue of $100 billion in 2022, largely due to the decline in COVID-related sales and upcoming patent expirations. However, the company's robust pipeline, recent FDA approvals, and acquisitions position it for future growth. CEO Albert Bourla's significant investment in Pfizer stock and the company's strong financials, including a 6.20% yield and A-rated debt, make it an attractive buy, despite short-term challenges.